(Q37303846)

19 August 2017

title

Hematopoietic SCT for peripheral T-cell lymphoma (English)

1 reference

19 August 2017

A Gutiérrez

1

1 reference

19 August 2017

M D Caballero

series ordinal

2

1 reference

19 August 2017

G Pérez-Manga

series ordinal

3

1 reference

19 August 2017

J Rodriguez

series ordinal

4

1 reference

19 August 2017

language of work or name

English

0 references

publication date

20 October 2008

1 reference

Bone Marrow Transplantation

19 August 2017

published in

1 reference

19 August 2017

volume

42

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

773-781

1 reference

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Impact of high-dose chemotherapy on peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Purine analogues in advanced T-cell lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Clinical experience with denileukin diftitox (ONTAK).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.332

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.332

1 reference

19 August 2017

1 reference